243 related articles for article (PubMed ID: 30319966)
1. Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.
Di Nunno V; Gatto L; Santoni M; Cimadamore A; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Massari F
Front Oncol; 2018; 8():397. PubMed ID: 30319966
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.
Mollica V; Di Nunno V; Santoni M; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Mariani C; Battelli N; Montironi R; Massari F
Expert Rev Mol Diagn; 2020 Feb; 20(2):207-217. PubMed ID: 31640441
[No Abstract] [Full Text] [Related]
3. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
4. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ekeke ON; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis C; Mahal B; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro CJ; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur J Cancer; 2023 May; 185():178-215. PubMed ID: 37003085
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel.
Mukhtar E; Worroll D; Galletti G; Schuster S; Piha-Paul SA; Giannakakou P
Cancer Drug Resist; 2020; 3(3):636-646. PubMed ID: 33062959
[TBL] [Abstract][Full Text] [Related]
6. Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report.
Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jun; 19(1):562. PubMed ID: 31185946
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.
Graf RP; Hullings M; Barnett ES; Carbone E; Dittamore R; Scher HI
Eur Urol; 2020 Feb; 77(2):170-177. PubMed ID: 31648903
[TBL] [Abstract][Full Text] [Related]
8. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
9. Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer.
Tulpule V; Morrison GJ; Falcone M; Quinn DI; Goldkorn A
Curr Oncol Rep; 2022 Oct; 24(10):1287-1298. PubMed ID: 35575959
[TBL] [Abstract][Full Text] [Related]
10. The role of liquid biopsies in prostate cancer management.
Kim CJ; Dong L; Amend SR; Cho YK; Pienta KJ
Lab Chip; 2021 Sep; 21(17):3263-3288. PubMed ID: 34346466
[TBL] [Abstract][Full Text] [Related]
11. The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer.
van Soest RJ; Efstathiou JA; Sternberg CN; Tombal B
Eur Urol Focus; 2016 Dec; 2(5):480-487. PubMed ID: 28723513
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy and prostate cancer. Current evidence applied to clinical practice.
Puche-Sanz I; Rodríguez-Martínez A; Garrido-Navas MC; Robles-Fernández I; Vázquez-Alonso F; Álvarez Cubero MJ; Lorente-Acosta JA; Serrano-Fernández MJ; Cózar-Olmo JM
Actas Urol Esp (Engl Ed); 2020 Apr; 44(3):139-147. PubMed ID: 31839360
[TBL] [Abstract][Full Text] [Related]
13. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer.
Casanova-Salas I; Athie A; Boutros PC; Del Re M; Miyamoto DT; Pienta KJ; Posadas EM; Sowalsky AG; Stenzl A; Wyatt AW; Mateo J
Eur Urol; 2021 Jun; 79(6):762-771. PubMed ID: 33422353
[TBL] [Abstract][Full Text] [Related]
14. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy Based Circulating Biomarkers in Metastatic Prostate Cancer.
Dathathri E; Isebia KT; Abali F; Lolkema MP; Martens JWM; Terstappen LWMM; Bansal R
Front Oncol; 2022; 12():863472. PubMed ID: 35669415
[TBL] [Abstract][Full Text] [Related]
16. Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
Li J; Gregory SG; Garcia-Blanco MA; Armstrong AJ
Crit Rev Clin Lab Sci; 2015; 52(4):191-210. PubMed ID: 26079252
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives.
Crocetto F; Russo G; Di Zazzo E; Pisapia P; Mirto BF; Palmieri A; Pepe F; Bellevicine C; Russo A; La Civita E; Terracciano D; Malapelle U; Troncone G; Barone B
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805043
[TBL] [Abstract][Full Text] [Related]
18. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers.
Pereira-Veiga T; González-Conde M; León-Mateos L; Piñeiro-Cid R; Abuín C; Muinelo-Romay L; Martínez-Fernández M; Brea Iglesias J; García González J; Anido U; Aguín-Losada S; Cebey V; Costa C; López-López R
Clin Exp Metastasis; 2021 Apr; 38(2):239-251. PubMed ID: 33635497
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
